Socioeconomic inequalities may affect cancer-specific survival and overall survival in patients with squamous cell carcinoma of the anus.
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.
Does First-Line Targeted Therapy Plus Immunotherapy Produce Durable Responses in ALK-Positive NSCLC?
A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses.
Recent efforts to develop and validate a patient-reported assessment of the quality of palliative cancer care have been successful.
Long-term data show that a CAR-T therapy induces significant clinical benefit without added adverse events among patients with refractory aggressive non-Hodgkin lymphoma.
A new study suggests the strength of evidence cited by the National Comprehensive Cancer Network to support recommendations deviating from FDA-approved therapy recommendations is not robust.
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
Heightened self-efficacy for symptom management in patients with hematologic cancers prior to undergoing stem cell transplant may be used in improving symptom management and outcomes.
The US Food and Drug Administration has approved a 4-week dosing schedule for a commonly used cancer therapy.
Limited evidence exists that supports the use of most circulating tumor DNA assays in the diagnosis or management of early-stage or advanced solid tumors, according to an expert review.